• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cns Pharmaceuticals Inc (NQ: CNSP )

    0.1100 -0.0008 (-0.72%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cns Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
    Via Investor Brand Network
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM
    Via Investor Brand Network
    Exposures Product Safety
    Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
    Via ACCESSWIRE
    CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
    Via ACCESSWIRE
    CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
    Via ACCESSWIRE
    CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Light, Viruses Could Transform Brain-Tumor Treatment
    Via Investor Brand Network
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
    Via Investor Brand Network
    Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
    Via Investor Brand Network
    Topics Death
    Exposures Death
    How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
    Via ACCESSWIRE
    How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
    Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM... 
    Via Benzinga
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
    Via Investor Brand Network
    CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
    Via ACCESSWIRE
    Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
    Via Investor Brand Network
    Topics Death
    Exposures Death
    CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
    Via ACCESSWIRE
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
    Via Investor Brand Network
    CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
    Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM... 
    Via Benzinga
    CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
    Via ACCESSWIRE
    Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
    Via Investor Brand Network
    Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain
    Via Investor Brand Network
    Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment
    Via Investor Brand Network
    Topics Cannabis
    Exposures Cannabis
    BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
    Via Investor Brand Network
    BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference
    Via Investor Brand Network
    Sonobiopsy Promises Easier Way to Diagnose Brain Tumors
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.